Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – a study of the United Kingdom Children's Cancer Study Group

The administration of 13-cis-retinoic acid (13-cisRA), following myeloablative therapy improves 3-year event-free survival rates in children with high-risk neuroblastoma. This study aimed to determine the degree of inter-patient pharmacokinetic variation and extent of metabolism in children treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Veal, G J, Cole, M, Errington, J, Pearson, A D J, Foot, A B M, Whyman, G, Boddy, A V
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360017/
https://www.ncbi.nlm.nih.gov/pubmed/17224928
http://dx.doi.org/10.1038/sj.bjc.6603554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360017/
https://www.ncbi.nlm.nih.gov/pubmed/17224928
http://dx.doi.org/10.1038/sj.bjc.6603554

Ejemplares similares